CohBar, Inc. (CWBR)
Stock Price:
$1.63 USD
0.09 (5.84%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
70.37M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-14.34M |
| Shares Out |
43.17M |
| EPS (ttm) |
-0.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$1.63 |
| Previous Close |
$1.54 |
| Change ($) |
0.09 |
| Change (%) |
5.84% |
| Day's Open |
1.56 |
| Day's Range |
1.46 - 1.64 |
| Day's Volume |
186,338 |
| 52-Week Range |
0.87 - 4.25 |
More Stats
| Market Cap |
70.37M |
| Enterprise Value |
63.65M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
43.17M |
| Float |
29.14M |
| EPS (basic) |
-0.33 |
| EPS (diluted) |
-0.33 |
| FCF / Share |
-0.23 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
56,083 |
| Short Ratio |
0.36 |
| Short % of Float |
0.19% |
| Beta |
2.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.93 |
| Revenue |
n/a |
| Operating Income |
-13.04M |
| Net Income |
-14.34M |
| Free Cash Flow |
-9.84M |
| Net Cash |
6.72M |
| Net Cash / Share |
0.16 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-51.98% |
| ROE |
-132.42% |
| ROIC |
-151.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -12.58 | -15.33 | -9.86 | -6.08 | -3.87 | -1.81 | -0.87 |
| Net Income | -13.04 | -15.71 | -9.83 | -6.07 | -3.88 | -1.82 | -0.87 |
| Shares Outstanding | 42.82 | 41.25 | 37.48 | 33.13 | 32.04 | 12.92 | 12.92 |
| Earnings Per Share | -0.30 | -0.38 | -0.26 | -0.18 | -0.12 | -0.14 | -0.07 |
| Operating Cash Flow | -10.11 | -10.13 | -7.63 | -5.20 | -3.63 | -0.84 | -0.71 |
| Capital Expenditures | -0.15 | -0.42 | - | -0.09 | -0.23 | - | - |
| Free Cash Flow | -10.26 | -10.55 | -7.64 | -5.29 | -3.86 | -0.84 | -0.71 |
| Cash & Equivalents | 12.56 | 22.18 | 8.45 | 8.69 | 10.29 | 1.20 | 0.27 |
| Total Debt | 3.36 | 2.92 | - | 0.21 | 0.21 | 0.20 | 0.20 |
| Net Cash / Debt | 9.21 | 19.27 | 8.45 | 8.48 | 10.09 | 0.99 | 0.07 |
| Assets | 13.53 | 23.04 | 8.86 | 9.59 | 10.60 | 1.97 | 0.32 |
| Liabilities | 5.40 | 5.08 | 1.24 | 0.89 | 0.79 | 0.90 | 0.35 |
| Book Value | 8.14 | 17.96 | 7.62 | 8.70 | 9.81 | 1.07 | -0.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CohBar, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Steven B. Engle |
Stock Information
| Ticker Symbol |
CWBR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CWBR |
Description
CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of diseases associated with aging and metabolic dysfunction. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular disease, and neurodegenerative disease, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel optimized analog of the MOTS-c mitochondrial-derived peptide for the treatment of NASH and obesity. The company was founded in 2007 and is headquartered in Menlo Park, California.